INOVIQ LTD — Capital/Financing Update 2018

Nov 18, 2018

==> picture [155 x 46] intentionally omitted <==

19 NOVEMBER 2018

ENTITLEMENT ISSUE CLEANSING NOTICE

This notice is given by BARD1 Life Sciences Limited (ASX: BD1) ( Company ) under section 708AA(2)(f) of the Corporations Act 2001 (Cth) ( Act ), as modified by the Australian Securities and Investments Commission ( ASIC ).

The Company announced on 8 November 2018 a non-renounceable pro rata entitlement offer to shareholders with a registered address in Australia, New Zealand and Switzerland ( Eligible Shareholders ) of 1 fully paid ordinary share ( New Share ) for every 5 shares held on the record date of 22 November 2018 ( Record Date ), at an issue price of $0.02 per New Share, to raise approximately $3.3 million (before costs) ( Entitlement Issue ).

The Company advises that:

1. the Company will offer the New Shares under the Entitlement Issue without disclosure to investors under Part 6D.2 of the Act;

2. this notice is being given under section 708AA(2)(f) of the Act as modified by ASIC;

3. as at the date of this notice, the Company has complied with:

   • (a) the provisions of Chapter 2M of the Act as they apply to the Company;

   • (b) section 674 of the Act; and

4. as at the date of this notice, there is no excluded information as defined in sections 708AA(8) and 708AA(9) of the Act; and

5. the potential effect that the Entitlement Issue will have on the control of the Company, and the consequences of that effect, will depend on a number of factors, including investor demand and existing shareholdings. As the Entitlement Issue is a pro rata issue, and given the current level of holdings of substantial holders (based on substantial holder notices that have been given to the Company and lodged with ASX before the date of this announcement), the Entitlement Issue is not expected to have any material effect or consequence on the control of the Company.

• ENDS -

FOR MORE INFORMATION PLEASE CONTACT:

Peter Gunzburg Dr Leearne Hinch Chairman CEO E peter@bard1.com E leearne@bard1.com M +61 400 414 416

ABOUT BARD1 LIFE SCIENCES LTD

BARD1 Life Sciences Ltd (ASX:BD1) is an Australian-based biotechnology company focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer. BARD1’s proprietary technology platform is based on novel tumour markers with potential diagnostic and therapeutic applications across multiple cancers. The pipeline includes BARD1 autoantibody tests in development for early detection of breast, ovarian and lung cancers. Additional diagnostic projects will be evaluated for other cancers. The company also has a cancer vaccine project at research-stage for treatment of cancer. BARD1 is committed to transforming the early detection of cancer to save lives. For more information on BARD1, see www.bard1.com.

BARD1 Life Sciences Limited (ABN 58 009 070 384) Registered Office | Suite B1, Tempo Building, 431 Roberts Road, Subiaco WA 6008, Australia P +618 9381 9550 | F +618 9388 7559 | E info@bard1.com | W www.bard1.com